Ceylad kicks off SHRINK trial targeting metastatic colorectal patients
Celyad has kicked off the SHRINK trial, a third clinical trial with its lead product candidate CYAD-01 (CAR-T NKG2D), targeting metastatic colorectal patients, the company said Thursday.